We claim:

1. A polypeptide comprising a first amino acid sequence present in a von willebrand factor (vWF) polypeptide and a second amino acid sequence heterologous to the first, wherein the polypeptide is capable of binding a Factor VIII (FVIII), with the proviso that the polypeptide lacks von willebrand factor (vWF) domains ~~A1, A2, A3,~~ D4, B1, B2, B3, C1, C2~~,~~ and CK, wherein the second amino acid sequence is C-terminus to the first amino acid sequence, ~~, or a combination thereof,~~

~~2. The polypeptide of claim 1,~~ wherein the first amino acid sequence is as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15~~, SEQ ID NO:33, SEQ ID NO:34, or SEQ ID NO:35~~, and wherein the second amino acid sequence corresponds to an immunoglobulin Fc.

~~3.~~2. The polypeptide of claim 1, wherein the polypeptide comprises the sequence set forth in SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 or~~,~~ SEQ ID NO:22~~, SEQ ID NO:36, SEQ ID NO:38 or SEQ ID NO:39~~.

~~4.~~3. The polypeptide of claim 1, wherein the polypeptide is capable of forming a dimer.

~~5. The polypeptide of claim 1, wherein the second amino acid sequence corresponds to an immunoglobulin Fc.~~

~~6.~~4. The polypeptide of claim 1, wherein the second amino acid sequence has the sequence set forth in SEQ ID NO:16.

~~7.~~5. A composition comprising the polypeptide of claim 1.

~~8.~~6. A protein complex comprising the polypeptide of claim 1~~-~~, and ~~the~~ a Factor VIII (FVIII) polypeptide.

~~9.~~7. A composition comprising the protein complex of claim ~~8~~6.

~~10.~~8. A nucleotide sequence encoding the polypeptide of claim 1.

~~11.~~9. The nucleotide sequence of claim ~~10~~8, wherein the nucleotide sequence is set forth in SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27~~,~~ or SEQ ID NO:28~~, SEQ ID NO:37, SEQ ID NO:42, or SEQ ID NO:43~~.

~~12.~~10. An expression vector comprising the nucleotide sequence of claim ~~10~~8.

~~13.~~11. A cell expressing the polypeptide of claim 1.

~~14.~~12. A cell expressing the protein complex of claim ~~8~~6.

~~15.~~13. An *in vitro* method for preparing the protein complex of claim ~~8~~6, the method comprising contacting the polypeptide with the Factor VIII (FVIII).

~~16.~~14. The method of claim ~~15~~13, wherein the contacting comprises recombinantly expressing the polypeptide in a cell that expresses the Factor VIII (FVIII).

~~17.~~15. An *in vitro* ~~-~~method for ~~preparing~~ binding a~~-~~ Factor VIII (FVIII), the method comprising: contacting ~~the~~ a Factor VIII (FVIII) polypeptide with ~~the~~ a polypeptide of claim 1 to form a protein complex comprising the polypeptide of claim 1 ~~-~~and the Factor VIII (FVIII).

~~18.~~16. The method of claim ~~17~~ 15 further comprising selectively adhering the complex to a resin comprising a binding partner having affinity for a domain defined by the second amino acid sequence.

~~19. The method of claim 18, wherein the second amino acid sequence corresponds to an immunoglobulin Fc.~~

~~20.~~17. The method of claim ~~19~~16, wherein the binding partner is a protein A or a protein G.

~~21.~~18. Use of a composition comprising the protein complex of claim ~~8~~6, in the manufacture of a medicament for enhancing a plasma pharmacokinetic property of a Factor VIII (FVIII).

~~22.~~19. The use of claim ~~21~~18, wherein the property is extended plasma half-life.

~~23.~~20. A composition comprising the protein complex of claim ~~8~~6, and a pharmaceutically acceptable carrier.

~~24.~~21. Use of the composition of claim ~~23~~ 20 in the manufacture of a medicament for treating ~~a blood condition.~~

~~25. The use of claim 24, wherein the condition is~~ hemophilia.